Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for MDNA55 (Bizaxofusp) in Glioblastoma, Cancer. The expected timing is based on the latest available company guidance and may change.
06/26/26:- Bizaxofusp recurrent GBM clinical data expected Q4 2026. Partnership efforts continue. 08/14/26:- Updated bizaxofusp clinical data will be presented at an upcoming conference. Recurrent glioblastoma data is expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.